Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of LCTX will rise by +0.33% over the next 2 Weeks and hit $1.52 by Thursday, May 14, 2026. In that time frame, LCTX's share price is expected to range between $1.43 and $1.59.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| May 14, 2026 | 1.43 | 1.52 | 1.59 |
| May 13, 2026 | 1.45 | 1.53 | 1.60 |
| May 12, 2026 | 1.47 | 1.54 | 1.61 |
| May 11, 2026 | 1.43 | 1.51 | 1.58 |
| May 8, 2026 | 1.42 | 1.49 | 1.56 |
| May 7, 2026 | 1.42 | 1.50 | 1.57 |
| May 6, 2026 | 1.44 | 1.51 | 1.58 |
| May 5, 2026 | 1.45 | 1.52 | 1.59 |
| May 4, 2026 | 1.42 | 1.49 | 1.56 |
| May 1, 2026 | 1.39 | 1.47 | 1.54 |
LCTX shares rose +1.32% in Friday, May 1, 2026's trading session, rising from a previous close of $1.51 to move at $1.53. The stock demonstrated notable intraday movement (see LCTX's key stats for a full breakdown), fluctuating between $1.49 and $1.55, a +4.03% trading range. While recent weeks have seen some volatility, LCTX has managed to secure a -6.71% drop over the past 2 weeks. The upward price movement was accompanied by decreased trading volume, with approximately 1.83M shares changing hands, 446.44K fewer than the previous session. This amounted to $2.80M in total market activity.
Will LCTX Continue Its Upward Trend?
According to analyst ratings and projections for LCTX, Lineage Cell Therapeutics, Inc. shares are anticipated to increase by +3.70%, potentially reaching $1.59 per share by May 14, 2026. Short-term technical indicators currently suggest a neutral sentiment for LCTX. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 13 positive trading days within the past 30 sessions. Based on the LCTX stock forecast, now is a good time to buy LCTX stock because its current trading price is +0.99% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on LCTX covering social and institutional perspectives.
LCTX Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into LCTX's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 45.09% to 46.10%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 48.17%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 50.35%, maintains a neutral outlook for the long term. Insights into LCTX's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Lineage Cell Therapeutics Short-Term Forecasts
LCTX Forecast For Next 5 Days
Our algorithm anticipates Lineage Cell Therapeutics (LCTX) stock could hit $1.54 by May 08, 2026. This represents a +0.70% fall from today's price, following a -6.25% change over the past five days.
LCTX Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Lineage Cell Therapeutics, Inc. (LCTX) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $1.47, which would mean a -3.92% decrease from the current price of $1.53. Projections for this period range from a high of $1.70 to a low of $1.17.
LCTX Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Lineage Cell Therapeutics's price over the next three months point to a rise. LCTX stock is expected to peak at $20.42 on Jul 27, 2026 after potentially dipping to $12.75 on Jun 04, 2026. On average, LCTX is likely to trade around $16.28 in the coming 90 days.
Lineage Cell Therapeutics Stock Forecast 2025
Based on our predictive models, Lineage Cell Therapeutics (LCTX) is expected to trade between $12.75 and $30.32 throughout 2026. This would result in an average price of $20.86, potentially offering investors a +1,263.40% return from current levels.
Lineage Cell Therapeutics, Inc. Monthly Forecast 2026–2027
May 2026
According to our latest forecast models, Lineage Cell Therapeutics, Inc. (LCTX) is positioned to show a strong performance in May 2026. The price is predicted to move between $13.37 and $17.30, settling at an average of $15.63. This could translate to a +921.57% gain.
June 2026
Based on current market signals, Lineage Cell Therapeutics, Inc. is projected to trend june 2026. We forecast a trading range from $12.75 to $16.29, with a likely average price of $14.57. Investors could expect a potential return of +852.29%.
July 2026
Our predictive algorithms indicate Lineage Cell Therapeutics, Inc. stock may see a shift in July 2026. The expected range spans $16.29–$20.42, with an average target of $18.48. This represents a positive outlook and a possible gain of +1,107.84%.
August 2026
Analyzing established trends, Lineage Cell Therapeutics, Inc. looks set to move in August 2026. Projections place the stock between $17.55 and $20.38, averaging around $18.49. This suggests a +1,108.50% gain from current levels.
September 2026
Market indicators suggest Lineage Cell Therapeutics, Inc. could experience notable changes during September 2026. Prices could fluctuate within $19.69 to $29.04, with a midpoint forecast of $23.29. The stock might deliver a +1,422.22% gain.
October 2026
Forecasting for October 2026, models estimate that Lineage Cell Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $26.36 and $30.23, averaging $27.13. This signals a positive trajectory with potential returns around +1,673.20%.
November 2026
According to our latest forecast models, Lineage Cell Therapeutics, Inc. (LCTX) is positioned to show a strong performance in November 2026. The price is predicted to move between $23.01 and $30.32, settling at an average of $24.79. This could translate to a +1,520.26% gain.
December 2026
Based on current market signals, Lineage Cell Therapeutics, Inc. is projected to trend december 2026. We forecast a trading range from $22.97 to $29.19, with a likely average price of $24.07. Investors could expect a potential return of +1,473.20%.
January 2027
Our predictive algorithms indicate Lineage Cell Therapeutics, Inc. stock may see a shift in January 2027. The expected range spans $22.33–$28.76, with an average target of $22.78. This represents a positive outlook and a possible gain of +1,388.89%.
February 2027
Analyzing established trends, Lineage Cell Therapeutics, Inc. looks set to move in February 2027. Projections place the stock between $22.22 and $30.72, averaging around $24.18. This suggests a +1,480.39% gain from current levels.
March 2027
Market indicators suggest Lineage Cell Therapeutics, Inc. could experience notable changes during March 2027. Prices could fluctuate within $19.76 to $30.25, with a midpoint forecast of $21.58. The stock might deliver a +1,310.46% gain.
April 2027
Forecasting for April 2027, models estimate that Lineage Cell Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $18.84 and $23.21, averaging $18.41. This signals a positive trajectory with potential returns around +1,103.27%.
LCTX's history of dividends and stock splits also plays a role in long-term investor confidence.

